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This study examines the prognostic significance of pathologic
factors in patients with primary locally advanced rectal cancer treated
prospectively with preoperative radiotherapy. From 1992 to 1998, 104
patients with rectal cancer of grades T3 or T4 and any N underwent
preoperative radiotherapy followed by surgical resection. Survival
curves were estimated according to the Kaplan-Meier method. Cor-
relation of outcome with clinicopathologic variables (pathologic tu-
mor and lymph node staging, histology, radial resection margin
[RRM], clearance, vessel involvement, and tumor regression grade
[TRG], quantitated in 5 grades) was evaluated using the Cox propor-
tional hazards model. None of the patients achieved a histologically
confirmed complete pathologic response, but 79% of the patients
showed partial tumor regression (TRG2–4) and 21% did not show
any tumor regression (TRG5). Among the tumors, 22% were of a
mucinous type. The RRM was free of tumor in 76% of the surgical
specimens. The median clearance was 2 mm. Vascular invasion was
present in 37 cases (36%). In the univariate analysis, lymph node
metastases, absence of tumor regression, positive RRM, and vascular
invasion were correlated with adverse overall survival and disease-
free survival; absence of tumor regression, positive RRM, and clear-
ance <2 mm were correlated with local recurrences; and advanced
pT stage was correlated only with disease-free survival. However, in
the multivariate analysis, only lymph node metastases and RRM were
independent prognostic factors for overall survival and disease-free
survival, and clearance <2 mm was an independent prognostic factor
for local control. Pathologic parameters remain strong determinants
of local recurrence and survival in locally advanced rectal cancer,
treated preoperatively with hyperfractionated and accelerated radio-
therapy. We show that patients with advanced pT, positive lymph
nodes, vascular invasion, positive RRM, clearance <2 mm, or ab-
sence of tumor regression are known to have poor clinical outcome.
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Colorectal cancer is a significant cause of morbid-
ity and mortality in Western populations. More than
1/3 of cases occur in the rectum, with an outcome after
surgery less favorable than for colon cancer, as re-
flected in local recurrence rates of 20% to 50% after
traditional surgical treatment.1 Moreover, rectal cancer
is characterized by a higher incidence of regional
lymph nodes and distant metastases. Preoperative ra-
diotherapy has been shown to reduce local failure rates
and to improve overall survival.1-4 However, results of
different clinicopathologic studies are sometimes con-
tradictory, which might be related to the heterogeneity
in radiation treatment–related factors and clinical
stages. Absence of a standardized method for patho-
logic analysis might be another source of discrepancies.
We have adopted a treatment schedule that aims to
accelerate the treatment to counter tumor proliferation
during treatment and to reduce the risk of late compli-
cations by hyperfractionation (ie, reducing the dose
per fraction). This hyperfractionated accelerated radio-
therapy (HART) schedule was tested in locally ad-
vanced rectal cancer, that is, T3 and T4 and any N, or
any T but N, rectal cancers.5,6 We demonstrated that
preoperative HART is feasible and is associated with a
lower toxicity than postoperative radiotherapy.5 Based
on this initial experience, a phase II trial was initiated.
Whether or not classical predictive factors of sur-
vival for colorectal cancer are still important after neo-
adjuvant therapy is a question frequently asked by pa-
thologists, and only sporadic studies with a systematic
pathologic approach try to answer it. In this study we
attempted to correlate response to radiotherapy with
pathologic variables and to determine which patho-
logic variables, including histological assessment of re-
sponse to radiotherapy, correlated with disease out-
come.
PATIENTS AND METHODS
The study group comprised 104 patients with locally
advanced rectal cancer recruited in a phase II trial (93-01) on
preoperative HART between 1992 and 1998. Assessment of
the clinical stage was based on digital rectal examination,
completed by both rectal ultrasonography and computed
tomography (CT) scan. During this time period, all patients
were eligible if they presented at preoperative work-up with
cT3 or cT4, regardless of the N stage. The HART protocol was
reviewed by the local ethics committee. All patients gave
informed consent. Patients with coexisting cancer or chronic
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inflammatory bowel disease were excluded from this study.
Most of the patients (90) underwent surgery in the Depart-
ment of Surgery, Hospital Center of the University of Vaudois
at Lausanne. Abdominoperineal resection was performed in
52 patients; low anterior resection, in 50 patients; and abdom-
inal transanal resection, in 2 patients. Although surgeons
claim that total mesorectal excision is a standard surgical
approach, we do not have the ability to assess whether this
surgical approach has been applied systematically. Patient age
ranged from 28 to 85 years (median, 63 years), and the
female/male ratio was 1.2. Before initiation of treatment, all
patients underwent complete clinical examination, endo-
scopic biopsy, blood count, renal and hepatic function assess-
ment, and carcinoembryonic antigen determination. Distant
metastatic disease was excluded by chest x-ray and abdominal
ultrasound or CT scan. Assessment of the local tumor exten-
sion was done by digital rectal examination, rectal ultrasound,
or CT scan.
According to cTNM staging based on digital rectal exam-
ination, rectal ultrasound, or CT scan,7 104 patients in this
cohort were clinically classified as stage T3–T4, and 27 were
N. Only 10 of the tumors were mobile, and 74 were fixed or
tethered. The status of the remaining tumors in terms of fixity
versus mobility was unknown. All patients were irradiated with
a linear accelerator with a minimal accelerating potential of 6
mV. The dose per fraction was 1.6 Gy (26 fractions), the
interfraction interval was at least 6 hours, and the total dose
was 41.6 Gy, given over 2.5 weeks. The time lapse between the
end of radiotherapy and surgical resection in most cases was
within 6 days (median, 5 days). Four patients who had a
positive resection margin and thus had no curative resection
(R1) received additional adjuvant chemotherapy after sur-
gery.
Macroscopic Assessment
The surgical specimens were opened through the ante-
rior wall and fixed in 10% buffered neutral formalin for 24
hours. The external surface of specimen was painted with
India ink to facilitate recognition of the circumferal margin,
also known as the radial resection margin (RRM). The entire
tumor and attached mesorectum were serially sliced at 3- to
4-mm intervals perpendicular to the longitudinal axis of the
rectum, which allowed macroscopic identification of the areas
of deepest invasion. These were sampled for histological con-
firmation. Tumors 5 cm in maximal dimension were in-
cluded in toto. For assessment of perirectal lymph nodes, the
mesorectal fat was removed after tumor sampling and cleared
in a carnoy solution for 24 hours, and all macroscopically
identifiable lymph nodes were submitted for histological ex-
amination.
Histological Assessment
Tissue samples were embedded in paraffin, cut, and
stained with hematoxylin and eosin. All rectal tumors were
retrospectively reanalyzed by 1 of the authors (B.H.). The
tumors were classified according to the World Health Orga-
nization classification system for tumors of the digestive sys-
tem and staged according to the TNM classification system.7,8
Tumor staging was based on the deepest infiltration of the
epithelial component of the cancer. An adenocarcinoma was
considered to be of the mucinous type if 50% of the tumor
was composed of mucin. The presence of tumor cells in lakes
of mucin was a prerequisite for a diagnosis of lymph node
metastatic mucinous carcinoma and for tumor staging. When
lakes of mucin found in the deepest part of a tumor were
devoid of tumor cells, they were not considered in the tumor
staging. When needed, staining with cytokeratins was per-
formed to detect isolated tumor cells into lakes of mucus.
Tumor downstaging was obtained by comparison of the cT
and pT stages.
Tumor regression was graded according to a method
described by Mandard et al9 for the assessment of pathologic
response after neoadjuvant chemoradiotherapy in esopha-
geal carcinomas and already used by our group in a previous
study on a series of rectal cancer treated with preoperative
radiotherapy.10 This method distinguishes 5 tumor regression
grades (TRGs), based on the presence of residual tumor cells
and the extent of fibrosis. TRG1 is defined as absence of
residual cancer and fibrosis extending through the different
layers of the rectal wall. TRG2 is characterized by rare residual
cancer cells scattered throughout the fibrosis (Fig 1A). TRG3
has more residual tumor cells, but fibrosis still predominates
(Fig 1B). In TRG4, residual cancer cells predominate in the
fibrosis (Fig 1C), and in TRG5, the tumor shows no signs of
regression (Fig 1D). Thus fibrosis induced by radiotherapy
was not included in the assessment of the tumor infiltration,
but it was used as a parameter of downstaging.
The clearance (ie, free distance between the tumor and
RRM) was measured on the sections in millimeters. Distal and
proximal resection margins, RRM, and the presence or ab-
sence of lymphatic or venous invasion were also recorded. No
distinction was made between venous or lymphatic involve-
ment by tumor and between extramural or intramural venous
invasion.
Statistical Analysis and Follow-Up
All patients were followed for local recurrence and dis-
tant metastasis every 6 months for the first 2 years and every
year thereafter. A physical examination, serum carcinoembry-
onic antigen assay, chest x-ray, abdominal ultrasound or CT
scan, and pelvic CT scan were included in the follow-up. The
events were death (all causes of death included) for overall
survival, distant metastases or locoregional relapse or death
for disease-free survival, and local or locoregional relapse for
local control. Patients who died without local or locoregional
relapse were censored at time of death.
All statistical analyses were conducted using the JMP
3.2.2 JUMP software (SAS Institute, Cary, NC). The 2 test was
used for the tests of correlation, and a P value 0.05 was
considered statistically significant. In univariate and multivar-
iate analysis, overall survival, disease-free survival, and local
control were used as the endpoints. In univariate analysis,
survival curves were estimated according to the Kaplan-Meier
method for the following pathologic variables: pT, pN, histol-
ogy, TRG, clearance, proximal and distal margins, RRM, and
vascular invasion. The significance of the differences was
estimated by the log-rank test. To increase the number of
patients per group, the categories of the different pathologic
variables were also combined for these analyses, that is, pT1–2
versus pT3–4, well and moderately differentiated adenocar-
cinomas versus poorly differentiated and mucinous carcino-
mas, and the responder group (TRG2–4) versus the nonre-
sponder group (TRG5).
Multivariate survival analysis according to the Cox pro-
portional hazards model was constructed by backward elimi-
nation of variables reaching a P value of 0.1 in the univariate
analysis. Thus the following parameters were selected for OS
and DFS: pT1–2 versus pT3–4, pN0 versus pN positive, re-
sponder group (TRG2–4) versus nonresponder group
(TRG5), RRM free, and vascular invasion. In comparison, the
following parameters were used for local control: responder
HUMAN PATHOLOGY Volume 34, No. 6 (June 2003)
542
group versus nonresponder group, RRM free, and clearance
2 mm. Patient age and sex were not included in the multi-
variate analysis, because these factors were not found to be
significantly associated with the aforementioned endpoints.
RESULTS
Pathologic Findings
All of the pathologic parameters analyzed are sum-
marized in Table 1. Of the 104 rectal cancer cases, 2
were pT1 (2%), 21 were pT2 (20%), 67 were pT3
(64%), and 14 were pT4 (14%). Of all patients, 44 had
a pT stage lower than the preoperatively assessed T
stage (43% of downstaging). Regional lymph node me-
tastases were found in 55 patients (53%), but no nodal
downstaging was seen. Of the tumors, 25% were well-
differentiated, 40% were moderately differentiated,
and 13% were poorly differentiated adenocarcinomas;
the remaining 22% were mucinous carcinomas. Muci-
nous carcinomas were most often found in patients
with pT3–4 (P  0.04).
None of the 104 tumors showed complete tumor
regression (TRG1). Partial tumor regression (TRG2–4)
was noted in 79% of the tumors, and no regression
(TRG5) was seen in 21% of the tumors. Of the regress-
ing tumors, 20% were TRG2, 39% were TRG3, and 20%
were TRG4. Advanced pathologic stages (pT3–4) fre-
quently showed no tumor regression (TRG5) (P 
0.01).
Median clearance was 2 mm. The total number of
patients with a clearance of 2 mm was 54 (52%).
Proximal and distal margins were free of tumor in all
patients but 1, in whom both the distal margin and the
RRM were positive. A positive RRM was found in 25
(24%) of all specimens. The other 79 patients (76%)
were considered to have had a curative resection (R0).
In 37 cases (36%), lymphatic invasion (23 cases) or
venous invasion (14 cases) was found.
Survival and Local Control
During follow-up (median, 40 months), 29 patients
developed distant metastasis (28%) and 8 developed
local recurrence (7.7%). Forty-five patients died, 34
from cancer. The median overall survival (OS) was 54
months, and the median disease-free survival (DFS) was
50 months. The actuarial locoregional recurrence rates
were 6.4% at 2 years and 7.6% at 5 years. Tumor
downstaging did not correlate with survival. The type of
surgical resection did not have any influence on sur-
vival or local control. Patient age and sex and tumor
differentiation did not correlated with outcome. The
correlation between the various pathologic variables
and outcome parameters are summarized in Table 2.
FIGURE 1. Tumor regression assessment of rectal carcinoma after preoperative radiotherapy. (A) Tumor showing rare residual
cancer cells scattered through the fibrosis (TRG2). (B) Tumor showing more residual tumor cells, but with fibrosis still predominating
(TRG3). (C) In TRG4, there are more residual cancer cells than fibrosis. (D) In TRG5, the tumor shows no signs of regression.
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Overall Survival
Median actuarial OS was significantly lower in pa-
tients with lymph node metastases (P  0.001). Tumor
differentiation was not correlated with survival even if
tumors were grouped into well-differentiated and mod-
erately differentiated adenocarcinomas versus poorly
differentiated and mucinous carcinomas. There was a
trend for histological response (TRG) to correlate with
OS (P  0.06). When grouped together, responders
(TRG2–4) showed significantly better overall survival
than nonresponders (TRG5) (P  0.02) (Fig 2A). OS
was worse in patients with a positive RRM (P  0.001)
(Fig 2B) and with vascular invasion (P 0.01) (Fig 2C).
Disease-Free Survival
Median actuarial DFS was significantly lower in
patients with advanced pT stages (pT3–4) (P  0.03)
and with lymph node metastases (P 0.0004). The DFS
was longer in responders (TRG2–4) than in nonre-
sponders (TRG5) (P  0.03). Moreover, a significant
correlation was found between the different grades of
tumor response and DFS (P  0.04) (Fig 3A). DFS was
also highly correlated with a positive RRM (P 0.0007)
(Fig 3B) and vascular invasion (P  0.005) (Fig 3C).
Local Control
The local control was better in responders (TRG2-
TRG4) than in nonresponders (TRG5) (P  0.02) (Fig
4A). Five of the patients with local recurrence had a
positive RRM, and all of them had a clearance less than
2 mm. The risk of local recurrence strongly correlated
with a positive RRM (P  0.001) (Fig 4B) and a clear-
ance 2 mm (P  0.005) (Fig 4C).
Multivariate Analysis
The results of multivariate analysis are summarized
in Table 3. Lymph node metastases and free RRM were
independent prognostic factors for OS and DFS,
whereas only clearance 2 mm remained an indepen-
dent prognostic factor for local control.
DISCUSSION
Both local recurrence and distant metastasis after
surgery remain major problems in the curative ap-
proach of rectal cancer. Local recurrence is often asso-
ciated with inadequate tumor resection.11 Major im-
FIGURE 2. OS of TRG, RRM, and vascular invasion studied by
univariate analysis in a series of 104 patients with primary lo-
cally advanced rectal cancer treated with preoperative ra-
diotherapy.
TABLE 1. Distribution of Histological Parameters in 104
Postirradiated Rectal Cancers






PN 0 49 47%
PN  55 53%
Tumor differentiation
Well differentiated 26 25%
Moderately differentiated 42 40%
Poorly differentiated 13 13%
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provements in the surgical control of local disease have
been made since the introduction of total mesorectal
excision.12-14 Nevertheless, the incidence of local recur-
rence remains high (20% to 40%).2,15 Randomized
studies have shown that preoperative radiotherapy de-
creases the risk of recurrences.13,15-22 Nonetheless, it
must be mentioned that most other series included
different Dukes’ stages, hindering comparison with our
series, which included only locally advanced rectal can-
cers.
The effect of preoperative radiotherapy on survival is
still controversial, with some studies showing a minimal
impact17,23 and others a significant impact.13,15,18,19,21 The
discrepancies among trials may be due to heterogeneity in
radiation treatment–related factors and differences in
clinical stages, as well as to absence of a standardized
method for pathologic analysis. Whether or not classical
predictive factors of survival for colorectal cancer are still
important after neoadjuvant therapy is a question fre-
quently asked by pathologists, and only sporadic studies
with a systematic pathologic approach have attempted to
answer it. A systematic pathologic workup is essential to
compare the results of preoperative radiotherapy among
different groups. We have reported previously that preop-
erative HART, an innovative schedule of radiotherapy in
rectal cancer, is feasible, improves the radical resection
rate, and induces a significantly lower acute toxicity com-
pared with postoperative radiotherapy.5,6
The aim of the present prospective study was to
evaluate the histological factors of prognostic value in a
series of patients with locally advanced rectal cancer
FIGURE 3. DFS of TRG, RRM, and vascular invasion studied by univariate analysis in a series of 104 patients with primary locally
advanced rectal cancer treated with preoperative radiotherapy.
TABLE 2. Correlation Between Histological
Parameters and Survival and Local Control in a Series
of 104 Patients With Rectal Cancer Treated With
Preoperative Radiotherapy
Histological parameter OS DFS Local control
pT1-2 versus pT3-4 p 0.1 p 0.03 p 0.7
pN stage p 0.001 p 0.0004 p 0.4
Tumor differentiation p 0.2 p 0.4 p 0.6
TRG 2-4 versus TRG5 p 0.02 p 0.03 p 0.02
Positive RRM p 0.001 p 0.0007 p 0.001
clearance  2mm p 0.9 p 0.7 p 0.005
Vascular invasion p 0.01 p 0.001 p 0.2
NOTE: P value  0.05.
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treated with a preoperative HART schedule. To this
end, we ensured meticulous standardization of speci-
men processing. We first paid attention to factors
known to adversely influence the risk of local recur-
rence or survival in rectal cancer treated with surgery
alone, including such tumor characteristics as tumor
stage, differentiation grade, tumor type, lymphatic or
venous invasion, RRM, and clearance.11,24,25 We also
looked at the prognostic role of tumor regression in
rectal cancers preoperatively treated by HART. We
found in this study, as in a previously reported study,10
that advanced pT was associated with a decreased DFS.
As expected, lymph node metastases correlated with
adverse outcome.26-28 We observed a higher incidence
of positive lymph nodes on pathologic examination
than by clinical staging. This finding is in disagreement
with some reports1,4,29,30 but in agreement with others
indicating a higher or unchanged number of lymph
node metastases.17,27,31,32 Our results underline the lack
of reliability of preoperative staging by radiologic tech-
niques and the need for meticulous analysis of lymph
nodes, which we attained by clearing the mesorectum.
In our series we found a mucinous carcinoma rate
of 22%, which is less than the rate of 33% reported in
1 series of nonirradiated rectal cancer.33 However, a
study by Nagtegaal et al34 comparing irradiated and
nonirradiated rectal carcinomas found that the irradi-
ated group had significantly more mucinous carcino-
mas. The authors hypothesized that irradiation might
induce changes in the consistency of mucin, causing
tumor expansion. However, in this case, one would
expect a shift to increased mucin in all tumors, which
FIGURE 4. Local control of TRG, RRM, and clearance studied by univariate analysis in a series of 104 patients with primary locally
advanced rectal cancer treated with preoperative radiotherapy.
TABLE 3. Multivariate Analysis in a Series of 104
Patients With Rectal Cancer Treated With
Preoperative Radiotherapy
Parameter Relative risk Confidence interval P value
OS
Lymph nodes positive 2.60 1.35-5.38 0.004
RRM free 0.68 0.50-0.93 0.02
DFS
Lymph nodes positive 3.39 1.69-7.53 0.0004
RRM free 0.66 0.48-0.90 0.01
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was not observed. Further research on the relationship
between radiation and the induction of mucinous car-
cinoma is merited.
In our series, the rate of poorly differentiated car-
cinomas was higher than the rate reported in a series of
nonirradiated rectal carcinomas (13% versus 5%).35
However, our result is in accordance with that of pre-
viously reported study of rectal cancer treated with
preoperative short-term radiation regimes,2 but not
with a trial using conventional long-term preoperative
radiotherapy schedules.4 This finding is difficult to ex-
plain, but it might suggest that the differentiated com-
ponent of a carcinoma is more radiosensitive and that
the poorly differentiated component persists after irra-
diation. However, even if we had observed a shift to-
ward a more important proportion of poorly differen-
tiated and mucinous carcinomas, these changes would
have no impact on survival, because we did not find any
correlation between tumor type and survival.
The significance of the presence of blood and
lymphatic vessel invasion after radiotherapy remains
unknown. We found in our study that vascular invasion
significantly decreased OS and DFS. The extent of
blood vessel invasion could be a criterion for selecting
patients with rectal cancer who may benefit from adju-
vant therapy. However, this finding needs to be con-
firmed by other studies.
The present study demonstrates the importance of
the RRM in the survival of patients with locally ad-
vanced rectal cancer treated preoperatively with radio-
therapy. The RRM was free of tumor in 76% of the
surgical specimens but was involved in 24% of the
patients, who thus had no curative resection. Although
we cannot exclude the possibility that nonstandard sur-
gery with a total mesorectal procedure is at the origin of
the high positive RRM rate, we can tentatively explain
this observation by the fact that only locally advanced
rectal cancer with a 72% of initially tethered or fixed
tumors were selected in this series, and the entire tu-
mors with their attached mesorectum were systemati-
cally sampled with special emphasis to detect positive
resection margins. Nevertheless, the actuarial locore-
gional recurrence rate at 5 years is only 7.6%. The
presence of tumor in the radial margin was strongly
associated not only with local recurrence, but also with
poor survival. Our results compare favorably with the
results of the preoperative radiotherapy Swedish Rectal
Cancer trial, in which the rate of local recurrence was
11%.1 However, our data cannot be compared directly
with data from the Dutch total mesorectal study, in
which the local recurrence rate was 2.4%.14,36 There are
several reasons for this. First, in the Dutch study there
were 30% of patients with stage I, whereas in our study
stage I was an exclusion criteria. Second, the results of
the Dutch study are given at 2 years, whereas we are
providing actuarial results at 5 years (median follow-up,
40 months). Finally, in the Dutch study there was ex-
tensive surgical training, which was not the case in our
study, because we were treating patients addressed by a
variety of surgeons.
In addition, we found that in patients without RRM
involvement but with clearance 2 mm, the local re-
currence rate was higher. In the multivariate analysis,
clearance remained an independent parameter for the
prediction of local recurrences. Although the deter-
mining factor for local control is a free RRM, quality
control of the surgical technique by standardized
pathologic examination of the specimen is by no means
the rule.14 Our results indicate that adequate his-
topathologic assessment not only of RRM, but also of
clearance provides clinically relevant parameters. Even
in the case of a negative RRM, the risk of local failure
remains high if clearance is 2 mm. Thus precise
assessment of RRM as well as clearance can justify fur-
ther treatment to prevent local recurrence. RRM in-
volvement is also important to the prediction of distant
metastases and survival.
We also demonstrated in the present series and a
previously reported series10 that tumor regression and
low residual tumor cell density are predictive factors of
survival in rectal cancer after preoperative radiother-
apy. Several clinical studies on the efficacy of preoper-
ative radiotherapy of rectal cancer correlated survival
with the presence or absence of residual tumor in the
surgical specimen.26,28 In the present series, 79% of the
patients showed histologically partial tumor regression,
whereas only 21% of patients showed no evidence of
tumor regression. We found that the TRG strongly
correlated with survival and local control. In addition,
in contrast with the findings of Berger et al,26 we found
that residual tumor cell density significantly correlated
with DFS. We found not a single case of complete
tumor regression after preoperative radiotherapy. Sev-
eral factors seem to determine tumor regression after
preoperative radiotherapy, including fraction size and
total dose applied.25,32 In randomized studies with a
dose of no more than 20 Gy, no downstaging or com-
plete histological tumor regression was found.24,32 Tu-
mor regression was reported with a total radiation dose
exceeding 20 Gy.1,3,19,27-30 Another factor is the time
interval between the end of radiotherapy and surgical
intervention. The optimal interval remains a matter of
debate. No complete tumor regression has been re-
ported when surgery is performed within a week after
the end of radiotherapy,1,17,19 a finding consistent with
our own data. In contrast, in studies with a longer
interval (10 days), complete histological regression is
observed in 2% to 11% of patients.15,26,28
Based on published data illustrating fast cellular ki-
netics in rectal cancer, we adopted a short delay in our
protocol to counter potential tumor repopulation.37,38 In
conclusion, because we are facing locally advanced tu-
mors and a short delay between the end of radiotherapy
and surgery, the lack of complete response is not unex-
pected. However, and most importantly, before a com-
plete tumor regression is diagnosed, the entire tumor
region must be sampled and carefully screened to detect
any small surviving foci of carcinoma.
This study showed that preoperative radiotherapy
decreased local recurrences in locally advanced tumors
even if those tumors are fixed. However, the high inci-
dence of distant metastases clearly illustrates the need
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to implement chemotherapy as soon as possible. In this
respect, we performed a phase I trial combining
CPT-11 and HART.39 To date, there is still no evidence
for the efficacy of chemotherapy in this setting.
In conclusion, histological assessment of those pa-
rameters classically recognized as prognostic factors for
nonirradiated colorectal cancer remains valuable for
rectal carcinoma treated with preoperative radiother-
apy. In addition, pathologists need to pay attention to
both the RRM and the clearance, because clearance2
mm is a very strong indicator of local failure.
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